1)Siddiqi HK, et al:COVID-19 illness in native and immunosuppressed states:a clinical-therapeutic staging proposal. J Heart Lung Transplant 39:405-407, 2020
2)日本版敗血症診療ガイドライン2020特別委員会COVID-19対策タスクフォース:COVID-19薬物療法に関するRapid/Living recommendations 第二版.2020
3)Beigel JH, et al:Remdesivir for the treatment of Covid-19-preliminary report. N Engl J Med 383:992-994, 2020
4)Ivashchenko AA, et al:AVIFAVIR for treatment of patients with moderate COVID-19:interim results of a Phase Ⅱ/Ⅲ multicenter randomized clinical trial. Clin Infect Dis, 2020[Online ahead of print]
5)RECOVERY Collaborative Group:Dexamethasone in hospitalized patients with Covid-19—preliminary report. N Engl J Med, 2020[Online ahead of print]
6)Matsuyama S, et al:The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting viral replication-transcription complex in culture cells. J Virol:JVI.01648-20, 2020[Online ahead of print]
7)Joyner MJ, et al:Effect of convalescent plasma on mortality among hospitalized patients with COVID-19:initial three-month experience. medRxiv:2020.08.12.20169359, 2020[Preprint]
8)Li L, et al:Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19:a randomized clinical trial. JAMA 324:460-470, 2020
9)Guaraldi G, et al:Tocilizumab in patients with severe COVID-19:a retrospective cohort study. Lancet Rheumatol 2:e474-e484, 2020
10)Campochiaro C, et al:Efficacy and safety of tocilizumab in severe COVID-19 patients:a single-centre retrospective cohort study. Eur J Intern Med 76:43-49, 2020
11)Long QX, et al:Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 26:1200-1204, 2020
12)To KK, et al:COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin Infect Dis:ciaa1275, 2020[Online ahead of print]